drugset / Trial / NCT00520910

Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers

NCT00520910 ↗

Phase 2 Completed 10 enrolled University of Miami
RandomizedParallel-groupSingle-blindBasic science

Summary

With this study, the investigators will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light.

Timeline

Start
2007-08
Primary completion
2009-05
Completion
2009-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Polypodium Leucotomos Unknown 7.5 mg/kg Oral

Indications